Shandong Ruishun Pharmaceutical Co., Ltd. is 27 kilometers away from the main factory area of Jingwei. It is located in Guchenghe Street, Ningyang Chemical Industry Park, Ciyao Town, Tai 'an City. It covers an area of 240 mu and was founded in 2021. The factory follows the international new concept to optimize the design and meet the highest requirements of international cGMP, intrinsic safety, environmental friendliness and occupational health.

The production workshop adopts a modular design combining "multi-function" and "specificity". The production line can be flexibly spliced and combined according to the requirements of different production processes, and the feeding, batching, dripping and reaction can realize automatic control of the whole process. Three-dimensional design is adopted, and the unit operation and the front and rear units are used to realize the transfer of unpowered materials; the central control room can realize the functions of whole process production monitoring, reading operation data, abnormal automatic alarm, remote guidance and disposal.

Energy supply through the computer to predict, analysis, pre-load operation mode to ensure maximum energy efficiency. "Three wastes" classification collection, classification processing, to achieve comprehensive utilization of energy. The waste water is treated for secondary use, the waste gas and waste solvent enter the RTO incineration, and the hot by-product steam generated by the incineration is used for production.

The company is in line with the China Drug Administration, the United States FDA, Europe EMEA, Japan PMDA regulatory requirements of green environmental protection, new high-standard GMP API factory, products will cover the world's mainstream drug market.

A professional product research and development team with 2 doctors and 28 masters and a total of 78 people has broken down technical barriers on the basis of the original research process and focused on the development of a series of new products such as olaparib and paliperidone, shortening the 8-9 step reaction of the original research process of foreign enterprises to 3-4 steps, and reducing the unit consumption from 89000 USD/kg to 11900 USD/kg.

The company has rich R & D pipelines and strategic layout at home and abroad. It has cooperative R & D centers in Europe, the United States and other countries. It has three domestic first-class R & D centers with independent intellectual property rights in Jinan and Tai'an. Quality research follows the latest international concept of "quality comes from design". The maximum single impurity is less than 0.02, far higher than the international USP standard.

More than 60 advantageous API projects have been developed and reserved, of which 15 products such as enzalutamide and olaparib have been developed in the central nervous system. Targeted anti-tumor drugs include 20 products such as imatinib mesylate, and respiratory drugs include 20 products such as salbutamol sulfate. 37 national invention patents have been declared, of which nano-drugs involve 6 types of drugs and 12 patents; botanical drugs involve 7 types of drugs and 25 patents. As a domestic first-line enterprise of inhalation preparations, a number of technologies are currently in the leading position in the field of inhalation preparations in China, and all industries will be transformed in the future.

Strengthen international cooperation, expand the global network layout, actively participate in the joint construction of the "Belt and Road", and have carried out trade exchanges with more than 10 countries along the "Belt and Road", respectively with well-known multinational pharmaceutical companies such as Pfizer in the United States, Merck in Germany, and AstraZeneca in the United Kingdom Establish long-term original research cooperation.

Shandong Ruishun Pharmaceutical Co., Ltd. will become a respected pharmaceutical company with professional competitive advantages and international competitiveness, pursuing the truth, goodness and beauty of drug production, ensuring high-quality, safe and effective drugs; preventing pollution, Protect the ecological environment; pay taxes in accordance with the law; create more employment opportunities; sincerely give back to the society. Create health value for the public with our innovation, quality and service.